synlogic Bringing the Transformative Power of Synthetic Biology to Medicine Corporate Presentation March 2021 synlogic © 2021 SYNLOGIC. CORPORATE PRESENTATION. ALL RIGHTS RESERVED. © 2021 SYNLOGIC. ALL RIGHTS RESERVED. | 1 Forward Looking Statements This presentation contains "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, ...

Financial Data and Key Metrics Changes - Research and development expenses for Q4 2020 were $11.4 million, slightly up from $11.3 million in Q4 2019, driven by collaborations and clinical study activities [59] - General and administrative expenses decreased to $3.3 million in Q4 2020 from $3.5 million in Q4 2019 [60] - The company reported a consolidated net loss of $14.6 million or $0.39 per share for Q4 2020, compared to a net loss of $12.8 million or $0.37 per share in the same period of 2019 [60] - No revenues were reported in Q4 2020, down from $1.2 million in Q4 2019 [61] - Cash, cash equivalents, and long-term investments at the end of Q4 2020 totaled $100.4 million, expected to fund operations into 2023 [62] Business Line Data and Key Metrics Changes - The metabolic disease pipeline includes SYNB1618 for PKU and SYNB8802 for Enteric Hyperoxaluria, both showing promising clinical data [28][30] - SYNB8802 demonstrated a 28.6% reduction in urinary oxalate levels compared to placebo in a dietary hyperoxaluria study [33][44] - SYNB1618 is currently in a Phase 2 study called SynPheny-1, with strong patient interest reported [18][54] Market Data and Key Metrics Changes - Enteric Hyperoxaluria has no approved treatments, representing a significant unmet need in the market [75] - The company is focusing on patients with severe disease manifestations, such as recurrent kidney stones and chronic renal insufficiency [75] Company Strategy and Development Direction - The company aims to demonstrate proof-of-concept in both lead metabolic programs later in 2021 [28] - The strategy includes leveraging synthetic biotic medicines to address various disease states, with a focus on advancing clinical candidates [12][14] - The appointment of Dr. Caroline Kurtz as Chief Development Officer is expected to enhance program leadership and development success [16][17] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the progress made in 2020 and the potential for significant clinical readouts in 2021 [27][28] - The company is well-positioned to advance its clinical programs, with cash reserves extending into 2023 [62] - Management highlighted the resilience and teamwork demonstrated during the past year, which has set the stage for meaningful advancements [27] Other Important Information - The company has initiated Part B of the Phase 1 study for SYNB8802, targeting patients with Enteric Hyperoxaluria [45] - The immunomodulation portfolio, including SYNB1891, is also advancing with updates expected in 2021 [26] Q&A Session Summary Question: How is Enteric Hyperoxaluria currently managed and where is the unmet need? - Management discussed the lack of approved treatments for Enteric Hyperoxaluria and the focus on patients with severe disease manifestations [75] Question: How does SYNB8802 differentiate from other approaches? - Management highlighted the unique mechanism of action and the potential for better efficacy in the upper GI tract compared to other treatments [78] Question: What are the expected effects of SYNB8802 in Enteric Hyperoxaluria patients? - Management anticipates that patients with higher baseline urinary oxalate levels will show greater reductions in urinary oxalate compared to healthy volunteers [134] Question: Will the new strain for PKU be introduced for Enteric Hyperoxaluria as well? - Management indicated that while there may be tweaks to the formulation, the current strain is expected to advance through development [88] Question: What is the safety profile of SYNB8802? - Management reported that the safety profile was similar to probiotics, with transient GI symptoms observed at higher doses [120] Question: What is the market opportunity for Enteric Hyperoxaluria? - Management noted that while Roux-en-Y surgeries are declining, other causes of Enteric Hyperoxaluria remain prevalent, ensuring a continued market need [123]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-37566 SYNLOGIC, INC. (Exact name of Registrant as specified in its Charter) (State or other jurisdiction of incorporation or organiza ...

synlogic Bringing the Transformative Power of Synthetic Biology to Medicine Corporate Presentation February 2021 synlogic © 2021 SYNLOGIC. CORPORATE PRESENTATION. ALL RIGHTS RESERVED. © 2021 SYNLOGIC. ALL RIGHTS RESERVED. | 1 Forward Looking Statements This presentation contains "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact ...

synlogic Bringing the Transformative Power of Synthetic Biology to Medicine Q3 Financial Results & Business Update 5 November 2020 synlogic © 2020 SYNLOGIC. QUARTERLY RESULTS. ALL RIGHTS RESERVED. © 2020 SYNLOGIC. QUARTERLY RESULTS. © 2020 SYNLOGIC. ALL RIGHTS RESERVED. RESERVED. | 1 | 1 Forward Looking Statements This presentation contains "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of ...

Synlogic, Inc. (NASDAQ:SYBX) Q3 2020 Results Earnings Conference Call November 5, 2020 8:30 AM ET Company Participants Daniel Rosan - Head, Corporate Finance & IR Aoife Brennan - President, CEO and Director Gregg Beloff - Interim CFO, Principal Acounting Officer & Principal Financial Officer Richard Riese - Chief Medical Officer David Hava - Chief Scientific Officer Conference Call Participants Tom Shrader - BTIG Mark Breidenbach - Oppenheimer Ted Tenthoff - Piper Sandler Operator Good morning. Welcome to S ...

synlogic Designed For Life Corporate Presentation August 2020 synlogic © 2020 SYNLOGIC. CORPORATE PRESENTATION. ALL RIGHTS RESERVED. © 2020 SYNLOGIC. ALL RIGHTS RESERVED. | 1 Forward Looking Statements This presentation contains "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this presentation regarding strategy ...

Synlogic, Inc. (NASDAQ:SYBX) Q1 2020 Earnings Conference Call May 7, 2020 8:00 AM ET Company Participants Elizabeth Wolffe - Head of Investor Relations & Corporate Communications Aoife Brennan - President & Chief Executive Officer Gregg Beloff - Interim Chief Financial Officer Richard Riese - Chief Medical Officer Conference Call Participants Mark Breidenbach - Oppenheimer Blair Cohen - H.C. Wainwright Ted Tenthoff - Piper Sandler Samantha Semenkow - Citigroup Joe Schwartz - SVB Leerink Julian Harrison - BT ...

synlogic DESIGNED FOR LIFE Corporate Presentation March 2020 synlogic © 2020 SYNLOGIC. ALL RI GHTS RESERVED. © 2020 SYNLOGIC. ALL RI GHTS RESERVED. || 1 Forward Looking Statements This presentation contains "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this presentation regarding strategy, future operations, f ...

Synlogic, Inc. (NASDAQ:SYBX) Q4 2019 Earnings Conference Call March 13, 2020 5:00 PM ET Company Participants Elizabeth Wolffe - Head, IR & Corporate Communications Aoife Brennan - President, CEO & Director Gregg Beloff - Interim CFO Richard Riese - CMO Conference Call Participants Joori Park - SVB Leerink Mark Breidenbach - Oppenheimer Samantha Semenkow - Citigroup Edward Tenthoff - Piper Jaffray Chris Howerton - Jefferies Julian Harrison - BTIG Operator Good afternoon. Welcome to Synlogic's Fourth Quarter ...